| Document Date: 2014-11-03 11:26:23
Open Document File Size: 74,38 KBShare Result on Facebook
City Osaka / / Company Schering-Plough Corp. / Merck & Co. Inc. / Dainippon Sumitomo Pharma Co. Ltd. / Shionogi & Co. Ltd. / Sanofi / Corporate Communications Department Shionogi & Co. Ltd. / / Country France / Japan / United States / / Event FDA Phase / / / IndustryTerm manufacturing / therapy for hypertension / foreign healthcare reforms / with respect to product / / MedicalCondition severe hypertension / hypertension / metabolic disorders / essential hypertension / / Organization Ministry of Health / / Person Isao Teshirogi / / / Position President & CEO / / Product Irbesartan / Trichlormethiazide / S-474474 / /
SocialTag |
Shionogi Files an Application for an Anti-hypertension Drug “S”, a Combination of Irbesartan and Trichlormethiazide Osaka, Japan, July 30, Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CE